Literature DB >> 32564516

Stable HEV IgG seroprevalence in Belgium between 2006 and 2014.

Erwin Ho1,2, Julie Schenk3,4, Veronik Hutse5, Vanessa Suin5, Amber Litzroth6, Stéphanie Blaizot4, Sereina A Herzog4, Vera Verburgh5, Marjorie Jacques5, Abbas Rahman7, Peter Michielsen1,2, Pierre Van Damme7, Steven Van Gucht5, Heidi Theeten7, Niel Hens3,4, Thomas Vanwolleghem1,2.   

Abstract

Recent European studies suggest an emergence of hepatitis E virus (HEV) infection. We evaluated trends in birth cohort-specific HEV seroprevalence and regional differences in Belgium. HEV IgG seroprevalence was analysed on national serum banks (1579 and 2087 samples for 2006 and 2014, respectively. Hepatitis E virus antigen was tested on positive samples. Observed data were modelled using a generalized additive model with a complementary log-log link. No significant differences between birth cohorts or sexes were found. Modelling identified the individual's age and province as relevant factors. The probability of HEV seropositivity increases significantly with age. An estimated total of 434 819 (yearly rate of 54,352) (sero-)infections were found between 2006 and 2014. Overall, HEV IgG seroprevalences were 4.1% (64/1579, 95% CI 3.1-5.1) and 5.8% (121/2087, CI 4.8-6.9) in 2006 and 2014, respectively. Observed HEV antigen seroprevalence was 0.027% (1/3666) for the entire cohort. These results show stable HEV IgG seroprevalence in Belgium.
© 2020 John Wiley & Sons Ltd.

Entities:  

Keywords:  Belgium; Europe; epidemiology; hepatitis E

Year:  2020        PMID: 32564516     DOI: 10.1111/jvh.13347

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  2 in total

1.  Treatment induced clearance of hepatitis E viruses by interferon-lambda in liver-humanized mice.

Authors:  Gulce Sari; Claudia E Mulders; Jingting Zhu; Gertine W van Oord; Zongdi Feng; Jolanda J C Kreeft-Voermans; Andre Boonstra; Thomas Vanwolleghem
Journal:  Liver Int       Date:  2021-08-29       Impact factor: 8.754

2.  Hepatitis E virus as a trigger for Guillain-Barré syndrome.

Authors:  Miriam Fritz-Weltin; Estelle Frommherz; Nora Isenmann; Lisa Niedermeier; Benedikt Csernalabics; Tobias Boettler; Christoph Neumann-Haefelin; Dominique Endres; Marcus Panning; Benjamin Berger
Journal:  BMC Neurol       Date:  2021-08-06       Impact factor: 2.474

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.